Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial

被引：0
|
作者：
Oya, M. [1 ]
Motzer, R. J. [2 ]
Choueiri, T. K. [3 ]
Haanen, J. B. A. G. [4 ]
Eto, M. [5 ]
Uemura, H. [6 ]
Venugopal, B. [7 ]
Rini, B. I. [8 ]
Miyake, H. [9 ]
Albiges, L. [10 ]
Schmidinger, M. [11 ]
Tomita, Y. [12 ,13 ]
Umeyama, Y. [14 ]
Ellers-Lenz, B. [15 ]
Hoffman, J. [16 ]
Larkin, J. [17 ]
机构：
[1] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[4] Netherlands Canc Inst, Amsterdam, Netherlands
[5] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan
[6] Kindai Univ, Fac Med, Dept Urol, Osakasayama, Japan
[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[8] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[9] Kobe Univ, Grad Sch Med, Div Urol, Kobe, Hyogo, Japan
[10] Inst Gustave Roussy, Villejuif, France
[11] Med Univ Vienna, Vienna, Austria
[12] Niigata Univ, Grad Sch Med, Dept Urol, Niigata, Japan
[13] Niigata Univ, Grad Sch Med, Dept Mol Oncol, Niigata, Japan
[14] Pfizer Japan Inc, Clin & Res Dept, Oncol, Shibuya Ku, Tokyo, Japan
[15] Merck Healthcare KGaA, Darmstadt, Germany
[16] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[17] Royal Marsden Hosp, London, England
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.312
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
292P
引用
收藏
页码：S1517 / S1518
页数：2
相关论文
共 50 条
  • [31] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Schmidinger, Manuela
    Quinn, David I.
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus J. M.
    di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    EUROPEAN UROLOGY, 2024, 85 (01) : 8 - 12
  • [32] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
    Tomita, Y.
    Motzer, R. J.
    Choueiri, T. K.
    Rini, B., I
    Miyake, H.
    Uemura, H.
    Albiges, L.
    Fujii, Y.
    Umeyama, Y.
    Wang, J.
    Mariani, M.
    Schmidinger, M.
    ESMO OPEN, 2022, 7 (02)
  • [34] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
    Froehner, Michael
    EUROPEAN UROLOGY, 2024, 86 (05)
  • [35] Exposure-response (E-R) analysis of efficacy for avelumab in combination with axitinib in patients with advanced renal cell carcinoma (aRCC) in JAVELIN Renal 101.
    Bello, Carlo
    Brar, Satjit
    Masters, Joanna C.
    Khandelwal, Akash
    Novakovic, Ana M.
    Ruiz-Garcia, Ana
    Hibma, Jennifer
    CANCER RESEARCH, 2021, 81 (13)
  • [36] Outcomes of patients who progressed while receiving avelumab plus axitinib (A plus Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.
    Albiges, Laurence
    Voss, Martin H.
    Rini, Brian I.
    Gravis, Gwenaelle
    Grimm, Marc-Oliver
    Nathan, Paul D.
    Bjarnason, Georg A.
    Tomita, Yoshihiko
    Penkov, Konstantin
    McGregor, Bradley
    Huang, Bo
    Thomaidou, Despina
    Mariani, Mariangela
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Avelumab plus axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post-marketing surveillance data by age
    Oya, Mototsugu
    Ito, Taito
    Sato, Masashi
    Morita, Makiko
    Kajita, Masahiro
    Nonomura, Norio
    CANCER MEDICINE, 2025, 14 (02):
  • [38] Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
    Larkin, James
    Oya, Mototsugu
    Martignoni, Marcella
    Thistlethwaite, Fiona
    Nathan, Paul
    Ornstein, Moshe C.
    Powles, Thomas
    Beckermann, Kathryn E.
    Balar, Arjun, V
    McDermott, David
    Gupta, Sumati
    Philips, George K.
    Gordon, Michael S.
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Wang, Jing
    Michelon, Elisabete
    di Pietro, Alessandra
    Choueiri, Toni K.
    ONCOLOGIST, 2022, : 333 - 340
  • [39] UK real-world observational study of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results.
    Nathan, Paul D.
    Charnley, Natalie
    Frazer, Ricky
    McGrane, John
    Muazzam, Iqtedar A.
    Rudman, Sarah
    Sharma, Anand
    Stevenson, Robert
    Hickey, Joseph David
    Tahim, Arpan
    Ritchie, Aimi Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [40] Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
    Choueiri, T. K.
    Larkin, J.
    Pal, S.
    Motzer, R. J.
    Rini, B., I
    Venugopal, B.
    Alekseev, B.
    Miyake, H.
    Gravis, G.
    Bilen, M. A.
    Hariharan, S.
    Chudnovsky, A.
    Ching, K. A.
    Mu, X. J.
    Mariani, M.
    Robbins, P. B.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ESMO OPEN, 2021, 6 (03)
12345